Browse All

Current Filters

CLEAR FILTER x

TITLE

The initial reduction in the percentage of peripheral lymphocytes and long disease course are associated with sustained response to Dimethyl Fumarate (DMF) in a small cohort of patients with Relapsing-Remitting Multiple Sclerosis

Siponimod Stabilizes Physical Disability Scores in People Living With Secondary Progressive Multiple Sclerosis After 2 Years of Treatment: Analysis From the Novartis Global Managed Access Program